Explore how advanced nanoparticle engineering is transforming formulation across both small and large molecule modalities. Dr. Chris Worrall highlights how Nanoform’s technologies enable higher drug‑loading oral tablets, ultra‑high‑concentration biologic formulations...
In this session, leading cell therapy CDMOs will break down how they support programs across development—from early process work through GMP manufacturing, scale-up, and commercial readiness—and where different approaches can...
In this session, leading CDMO experts will break down the key decisions across host cell selection, vector design, and clone screening strategies, and explain how those choices impact expression, scalability,...
Clinical trials sit at a unique intersection of science, patients, and clinical care, and for decades, the “gold standard” has prioritized the rigor of the data, often at the expense...
Join us for this digital event designed for pharmaceutical and biopharmaceutical companies seeking reliable CDMO partnerships to accelerate their microbial programs from development through commercial manufacturing. By attending this digital...
In this Capabilities Update, CDMOs will share how they support ADC programs from early development through clinical and commercial manufacturing. By attending this digital event, you will gain insight into...
Difficult to purify small molecules pose a big challenge for drug developers. Working with a CDMO that has specialized expertise in chromatography ensures that no matter the purification challenges or...
Given its inherent time and resource demands, variability in productivity, and the rising complexity of monoclonal antibody (mAb) modalities—including bispecific antibodies (bsAb) and fusion proteins—cell line development (CLD) has become...
As biomanufacturers face increasing pressure to boost productivity, reduce costs, and accelerate timelines, traditional scale-up approaches can introduce variability and performance drift. Intensified upstream processing offers a more scalable, efficient...
Study build inefficiency is rarely caused by a single failure point. Instead, delays accumulate across fragmented protocol interpretation, manual configuration, iterative amendments, and validation cycles that often surface issues late—when...
